# EDGAR Filing Document

**Accession Number:** 0001770069
**File Stem:** 0001388325-25-000021
**Filing Date:** 2025-11
**Character Count:** 16369
**Document Hash:** bd91c3775a0d6663e599d4237ae3525a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001388325-25-000021.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001388325-25-000021

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MapLight Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001770069
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832163243
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95298
- **FILM NUMBER:** 251449456

**BUSINESS ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-839-4360

**MAIL ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvarado Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190307
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Novo Holdings A/S
- **CENTRAL INDEX KEY:** 0001388325

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **ZIP:** 2900
- **BUSINESS PHONE:** 45 8824 8824

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **ZIP:** 2900

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Novo A/S
- **DATE OF NAME CHANGE:** 20070130

## Exhibit 99.1

EXHIBIT 99.1

SCHEDULE I

Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.

**Novo Holdings A/S**

---

| | | | |
|:---|:---|:---|:---|
| **Name, Title** | **Address** | **Principal Occupation** | **Citizenship** |
| Lars Rebien Sørensen<br> Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Steen Riisgaard<br> Vice Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Torsten Sløk <br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Economist of Apollo Global Management | USA<br> Denmark |
| Nirmal Prabhakar Narvekar<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | CEO of Harvard Management Company | USA |
| Jun Sung Kim<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Head of the endowment fund for the National University of Singapore, and main board member of Samsung Electronics, Korea | Singapore |
| Francis Michael Cyprian Cuss<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Biopharmaceutical Consultant  | United Kingdom |
| Viviane Monges<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | France |
| Henrik Poulsen<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Senior Advisor, A.P. Møller Holding and Professional Board Director | Denmark |
| Britt Meelby Jensen<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Ambu A/S | Denmark |
| Susanne Antonie Schaffert<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Germany |
| Lars Green,<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Kasim Kutay<br> Chief Executive Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Novo Holdings A/S | United Kingdom |
| Nigel Kevin Govett<br> Chief Financial Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Financial Officer,<br> Novo Holdings A/S | United Kingdom |

---

------

**Novo Nordisk Foundation**

---

| | | | |
|:---|:---|:---|:---|
| **Name, Title** | **Address** | **Principal Occupation** | **Citizenship** |
| Lars Rebien Sørensen<br> Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Lars Henrik Munch<br> Vice Chair of the Board | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Steen Riisgaard<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Lars Green<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professional Board Director | Denmark |
| Barbara Casadei<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | British Heart Foundation Professor of Cardiovascular Medicine, Honorary Consultant Cardiologist, and Head of the National Heart and Lung Institute at Imperial College London | Italy |
| Nana Bule Sejbaek<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Operating Advisor,<br> Goldman Sachs Asset Management and Professional Board Director | Denmark |
| Christopher Ashby Voigt<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Professor of Advanced Biotechnology and Department Head in Biological Engineering, Massachusetts Institute of Technology (MIT) | USA |
| Mads Boritz Grøn<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Quality Auditor,<br> Novo Nordisk A/S | Denmark |
| Ole Jakob Müller<br> Board Director | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Senior Environmental Specialist,<br> Novonesis | Denmark |
| Stig Strøbaek<br> Board Director  | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Electrician,<br> Novo Nordisk A/S | Denmark |
| Mads Krogsgaard Thomsen<br> Chief Executive Officer | Tuborg Havnevej 19<br> 2900 Hellerup<br> Denmark | Chief Executive Officer, <br> Novo Nordisk Foundation | Denmark |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**MAPLIGHT THERAPEUTICS, INC.**

*(Name of Issuer)*

**Voting Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**56565P103**

*(CUSIP Number)*

**Barbara Fiorini**<br>Novo Holdings A/S, Tuborg Havnevej 19<br>Hellerup G7 DK-2900<br>45 3527 6592

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/28/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **56565P103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Novo Holdings A/S** | Name of reporting person<br>**Novo Holdings A/S** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**G7** | Citizenship or place of organization<br>**G7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3686622.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**3686622.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3686622.00** | Aggregate amount beneficially owned by each reporting person<br>**3686622.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Voting Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
MAPLIGHT THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
800 Chesapeake Drive, Redwood City, CA, 94063

**Item 4. Purpose of Transaction**

Novo Holdings A/S purchased the aforementioned securities for investment purposes with the aim of increasing the value of its investments and the Issuer. Subject to applicable legal requirements, Novo Holdings A/S may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, other opportunities available to Novo Holdings A/S, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, Novo Holdings A/S may dispose of all or a portion of its securities of the Issuer at any time (including by means of programs adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Act")). Novo Holdings A/S reserves the right to increase or decrease its holdings on such terms and at such times as it may decide.

James D. Trenkle, Ph.D. is employed by Novo Holdings US, Inc., which provides consulting services to Novo Holdings A/S and was designated to the board of directors of the Issuer by Novo Holdings A/S in October 2023. Dr. Trenkle is not deemed to be a beneficial owner of the securities held by Novo Holdings A/S. Dr. Trenkle may engage in communications with the Issuer's other directors and members of management, and stockholders and third parties regarding the corporate governance, business, operations, strategy or future plans (including proposed corporate transactions of a significant nature) of the Issuer, including any plans or proposals regarding the same.

Except as set forth in this Item 4 and Item 6 below, Novo Holdings A/S does not have any plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, Novo Holdings A/S reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the common stock to become eligible for termination of registration under Section 12(g) of the Act. Novo Holdings A/S also retains the right to change its investment intent at any time, to acquire additional shares of common stock or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part of the common stock beneficially owned by it (or any shares of common stock into which such securities are converted) in any manner permitted by law. Novo Holdings A/S may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Novo Holdings A/S beneficially owns 3,686,622 shares of common stock representing approximately 8.4% of the Issuer's outstanding shares of common stock (the "Novo Shares"), based upon 43,641,422 shares of common stock outstanding as of the date of this report, as reported in the Issuer's prospectus dated October 26, 2025 filed with the Securities and Exchange Commission (the "SEC") on October 27, 2025.

**(b)**
Novo Holdings A/S is a Danish corporation wholly owned by the Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

**(c)**
Except as set forth herein, Novo Holdings A/S has not effected any transactions with respect to the Issuer's Common Stock during the past sixty days and neither the Foundation nor any person listed on Schedule I has effected any transactions in the Issuer's Common Stock within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Lock-up Agreements

The holders of all of the Issuer's pre-IPO capital stock, including Novo Holdings A/S, and each of the Issuer's directors and executive officers, entered into lock-up agreements (the "Lock-Up Agreements") with the representatives of the underwriters of the Issuer's IPO. Pursuant to the Lock-Up Agreements, Novo Holdings A/S is not permitted, with limited exceptions, for a period of 180 days from October 26, 2025, to dispose of or hedge any of the Issuer's securities, except with the prior written consent of Morgan Stanley & Co. LLC, Jefferies LLC and Leerink Partners LLC.

The foregoing description of the Lock-up Agreements is not complete and is qualified in its entirety by reference to the full text of the form of the lock-up agreement filed as Exhibit 99.2 to this Schedule 13D and incorporated by reference herein.

Investors' Rights Agreement

On July 18, 2025, the Issuer, Novo Holdings A/S and certain other parties entered into an amended and restated investors' rights agreement (the "Investors' Rights Agreement"). The Investors' Rights Agreement provides Novo Holdings A/S and other parties thereto with certain demand registration rights, including shelf registration rights, in respect of the shares of common stock issued to it upon conversion of the convertible preferred stock, subject to certain conditions. In addition, in the event that the Issuer registers additional shares of common stock for its own account or for the account of other holders of its securities, Novo Holdings A/S and certain other parties are entitled to include their shares in the registration, subject to certain limitations.

The registration rights will terminate on the earlier to occur of (a) the closing of certain liquidation events, or (b) such date after the closing of the IPO, as to any stockholder, all Registrable Securities (as defined in the Investors' Rights Agreement) held or entitled to be held upon conversion by such stockholder may immediately be sold under Rule 144 during any ninety (90) day period. The Investors' Rights Agreement contains customary cross-indemnification provisions, pursuant to which the Issuer is obligated to indemnify Novo Holdings A/S and other parties in the event of material misstatements or omissions in the registration statement attributable to the Issuer or any violation or alleged violation whether by action or inaction by the Issuer under certain securities laws and Novo Holdings A/S is obligated to indemnify the Issuer for material misstatements or omissions in the registration statement attributable to it, subject to certain limitations.

The description of the Investors' Rights Agreement contained in this Item 6 is qualified in its entirety by reference to the full text of the Investors' Rights Agreement filed as Exhibit 99.3 to this Schedule 13D and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Novo Holdings A/S

**Signature:** /s/ Barbara Fiorini

**Name/Title:** Novo Holdings A/S By Barbara Fiorini, General Counsel, Finance & Operations

**Date:** 11/04/2025